During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

Oncolytics Biotech (ONCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on ONCY stock, giving a Buy rating yesterday. John Newman has given ...